Open-label, single center, phase I trial to investigate the mass balance and absolute bioavailability of the oral c-Met inhibitor tepotinib

被引：0
|
作者：
Johne, A. [1 ]
Scheible, H. [2 ]
Becker, A. [1 ]
Van Lier, J. J. [3 ]
Meyring, M. [2 ]
机构：
[1] Merck KGaA, Global Early Dev, Darmstadt, Germany
[2] Merck KGaA, Inst Drug Metab & Pharmacokinet, Grafing, Germany
[3] Pharmaceut Res Assoc, Early Dev Serv, Zuidlaren, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)30232-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
369
引用
收藏
页码：S77 / S77
页数：1
相关论文
共 50 条
  • [21] A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers
    Bello, Carlo L.
    Smith, Evan
    Ruiz-Garcia, Ana
    Ni, Grace
    Alvey, Christine
    Loi, Cho-Ming
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (02) : 379 - 395
  • [22] A phase I, open-label, mass balance study of [14C] dacomitinib (PF-00299804) in healthy male volunteers
    Carlo L. Bello
    Evan Smith
    Ana Ruiz-Garcia
    Grace Ni
    Christine Alvey
    Cho-Ming Loi
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 379 - 385
  • [23] A phase I study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects
    Amakye, DD
    Hibberd, M
    Stevenson, SJ
    SLEEP, 2004, 27 : 54 - 54
  • [24] Identification of the recommended phase II dose (RP2D) of the c-Met Inhibitor tepotinib (MSC2156119J) in Japanese patients (pts) with solid tumors: A phase I trial
    Yamazaki, K.
    Tsushima, T.
    Shitara, K.
    Sarholz, B.
    Fujita, M.
    Doi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S75 - S76
  • [25] Data from a phase Ib/II trial of the oral c-Met inhibitor tepotinib (MSC2156119J) as first-line therapy in Asian patients with advanced hepatocellular carcinoma
    Qin, S.
    Lim, H. Y.
    Ryoo, B. Y.
    Li, C.
    Xiong, H.
    Ihling, C.
    Cheng, A. L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S452 - S453
  • [26] Phase I study of oral selective c-Met inhibitor EMD 1214063 in pts with advanced solid tumors.
    Falchook, Gerald Steven
    Hong, David S.
    Amin, Hesham M.
    Fu, Siqing
    Piha-Paul, Sarina Anne
    Janku, Filip
    Subbiah, Vivek
    Naing, Aung
    Wheler, Jennifer J.
    Klevesath, Manfred B.
    Koehler, Karola
    Johne, Andreas
    Bladt, Friedhelm
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] Open-label, single-dose, phase I study evaluating the mass balance and pharmacolkinetics (PKs) of sunitinib (SU) in healthy male subjects
    Sherman, L.
    Peng, G.
    Patyna, S.
    Pool, W.
    Smeraglia, J.
    Bello, C. L.
    Garrett, M.
    Klamerus, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 116 - 116
  • [28] THE EFFECT OF FOOD ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ICLEPERTIN (BI 425809), A GLYCINE TRANSPORTER 1 INHIBITOR, IN HEALTHY VOLUNTEERS: A PHASE I OPEN-LABEL, RANDOMIZED, CROSSOVER TRIAL
    Harada, Akiko
    Madari, Shilpa
    Jungnik, Arvid
    Breithaupt-Groegler, Kerstin
    Hohl, Kathrin
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2025, 28 : i360 - i361
  • [29] A Phase I, Open-label, Randomized, 2-Way Crossover Study to Evaluate the Relative Bioavailability of Intranasal and Oral Varenicline
    Nau, Jeffrey
    Wyatt, David J.
    Rollema, Hans
    Crean, Christopher S.
    CLINICAL THERAPEUTICS, 2021, 43 (09) : 1595 - 1607
  • [30] Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study
    Akifumi Kurata
    Hidetoshi Furuie
    Tomoko Ishizuka
    Takafumi Nakatsu
    Takako Shimizu
    Manabu Kato
    Yasuhiro Nishikawa
    Hitoshi Ishizuka
    Advances in Therapy, 2019, 36 : 1618 - 1627
12345